Stockscreener 앱 받기
0.175
1.57%
-0.0028
시장 영업 전:
.17
-0.005
-2.86%
전일 마감가:
$0.1778
열려 있는:
$0.1799
하루 거래량:
13.17M
Relative Volume:
1.22
시가총액:
$41.07M
수익:
$48.47M
순이익/손실:
$-170.37M
주가수익비율:
-0.2334
EPS:
-0.7499
순현금흐름:
$-171.35M
1주 성능:
-24.21%
1개월 성능:
-47.92%
6개월 성능:
-94.74%
1년 성능:
-86.11%
1일 변동 폭
$0.168
$0.18
1주일 범위
$0.168
$0.2352
52주 변동 폭
$0.1626
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.175 | 41.73M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-02-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2025-07-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
Gossamer Bio (NASDAQ: GOSS) awards 115K stock options to director - Stock Titan
Gossamer Bio (GOSS) director Skye Drynan awarded 115,000 stock options at $0.178 - Stock Titan
Gossamer Bio (GOSS) director receives 115,000 stock options as board compensation grant - Stock Titan
Director at Gossamer Bio (NASDAQ: GOSS) receives 115K stock options - Stock Titan
Gossamer Bio (GOSS) director awarded 115,000 stock options as compensation - Stock Titan
Gossamer Bio (NASDAQ: GOSS) awards director 115,000 stock options - Stock Titan
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Gossamer Bio, Inc. Announces Early Settlement and New Indenture for Senior Secured Convertible Notes Due 2030 - Minichart
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Gossamer Bio (NASDAQ: GOSS) swaps $181M converts for new debt, equity and warrants - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
"SERALUTINIB", THE ACTUAL DRUG IN THE "PROSERA" PHASE 3 CLINICAL TRIAL... "THE SICKER YOU ARE, THE BETTER IT WORKS"... "Bullish"... ( $45.00 ) BY ( JUNE 30, 2026 ) - Moomoo
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - BioSpace
GOSS: Gossamer Bio Announces Early Tender Results for Exchange O - GuruFocus
Gossamer Bio receives 90.5% tender in debt exchange offer By Investing.com - Investing.com Nigeria
Gossamer Bio receives 90.5% tender in debt exchange offer - Investing.com
How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals - Yahoo Finance
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Extends Early Tender Deadline for Convertible Note Exchange Offer to June 9 - geneonline.com
GOSS: Gossamer Bio Extends Tender Date for Convertible Notes Exc - GuruFocus
Gossamer Bio, Inc. Extends Early Tender Date for Exchange Offer and Consent Solicitation for Convertible Notes - Minichart
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
Gossamer Bio extends early tender date for exchange offer; $181.05M tendered, New Notes up to $72M - TradingView
Gossamer Bio (NASDAQ: GOSS) extends early tender deadline in major convertible note exchange - Stock Titan
Pomerantz LLP Notifies Shareholders of Lawsuit Filed Against Gossamer Bio, Inc. – GOSS - ACCESS Newswire
GOSS, Gossamer Bio Faces Class Action Lawsuit Over PROSERA Trial Results - GuruFocus
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who - GuruFocus
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - Business Wire
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of - GlobeNewswire
Pomerantz LLP Posts Reminder: Legal Action Filed Against Gossamer Bio, Inc. – GOSS - ACCESS Newswire
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) In - GuruFocus
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - PR Newswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus
GOSS DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class ActionGOSS - ACCESS Newswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. ... - Black Hills Pioneer
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses Ma - GuruFocus
GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - TradingView
GOSS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. ... - Black Hills Pioneer
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & - GlobeNewswire
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bi - GuruFocus
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - PR Newswire
The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of - GlobeNewswire
GOSS Stock Chart | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
GOSS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
Gossamer Bio Deadline: GOSS Investors with Losses in Excess of $100K Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit - PR Newswire
Gossamer Bio Inc stock (US38198T1034): shares in focus after securities lawsuit update and elevated - AD HOC NEWS
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.13%
3.22%
자본화:
|
볼륨(24시간):